Company Filing History:
Years Active: 2018
Title: Serenella Eppenberger-Castori: Innovator in Cancer Treatment Prediction
Introduction
Serenella Eppenberger-Castori is a notable inventor based in Riehen, Switzerland. She has made significant contributions to the field of cancer treatment, particularly in predicting the outcomes of anthracycline therapy for patients with cell proliferative disorders. Her innovative work has the potential to improve treatment efficacy and patient outcomes.
Latest Patents
Serenella holds a patent for "Markers for the prediction of outcome of anthracycline treatment." This invention relates to methods for predicting the effectiveness of anthracycline treatment by determining the expression levels of specific genes, including PITX2, TFF1, and PLAU. The patent also encompasses sequences, oligonucleotides, and antibodies that can be utilized in these predictive methods. She has 1 patent to her name.
Career Highlights
Throughout her career, Serenella has worked with various organizations, including Therawis Diagnostics GmbH and Epigenomics AG. Her experience in these companies has allowed her to collaborate with leading experts in the field and contribute to advancements in cancer research and treatment.
Collaborations
Some of her notable coworkers include John Foekens and John W. Martens. Their collaborative efforts have furthered the understanding of cancer treatment and the development of innovative solutions.
Conclusion
Serenella Eppenberger-Castori is a pioneering inventor whose work in predicting cancer treatment outcomes is making a significant impact in the medical field. Her contributions are essential for advancing personalized medicine and improving patient care.